Elan reports loss, in talks with many companies
UPDATE: Biotechnology company Elan posted a net operating loss of $72.8 million for the first quarter of 2013.
Biotechnology company Elan posted a net operating loss of $72.8 million for the first quarter of 2013, down from $74.7 million in the comparable period last year.
The company said that first quarter global sales of the MS drug Tysabri increased by 14 per cent to €456 million.
Elan recently completed the sale of its stake in Tysabri and said it now has about $2 billion in cash and cash equivalents as a result.
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine